AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04483297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Local Autologous Bone + Posterior Fixation
Study NCT03633591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Multiple doses of tolcapone tablets in the fasted state
Study NCT03633591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Modified Release Prototype
Description: A single dose of tolcapone modified release prototype in the fasted state
Study NCT03633591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Divided Dose
Description: Tolcapone (suspension) in equal divided doses in the fasted state
Study NCT03633591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Modified Release Prototype
Description: A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
Study NCT00722098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine & Cyclophosphamide
Description: Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.
Study NCT00722098 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DC Vaccine & Placebo
Description: Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.
Study NCT04240769 — intervention group
Intervention type: DEVICE
Intervention: Total or Partial Knee Arthroplasty
Description: Reconstruction of part or all of the native articulation at the knee joint via implant.
Study NCT03751111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
Study NCT04644055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EUS- share wave of the liver
Description: Evaluation of the right and left hepatic lobe with EUS-guided share wave
Study NCT01063218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emollient - Cetaphil Advanced
Description: Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
Study NCT00905268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Study NCT03751111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
Study NCT03323710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
Study NCT00905268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Study NCT03550365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bran bread intervention
Description: 4 week dietary intervention rich in rye bran bread
Study NCT03550365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bread intervention
Description: 4 week dietary intervention rich in rye bread
Study NCT03550365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bread diet
Description: 4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
Study NCT01107288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-based multitask exercises program
Description: Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
Study NCT01107288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Music-based multitask exercises program
Description: Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
Study NCT03323710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
Study NCT01578187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go
Description: Treatment with the device once under observation
Study NCT00798980 — intervention group
Intervention type: DRUG
Intervention: Mirena (BAY86-5028)
Description: Nulliparous Women
Study NCT03689348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avena sativa
Description: A supplement derived from wild green oat
Study NCT03689348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT00496470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort (budesonide/formoterol turbuhaler 320/9ug)
Description: Symbicort (budesonide/formoterol turbuhaler 320/9ug)
Study NCT00496470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva (tiotropium bromide 18ug)
Description: Spiriva (tiotropium bromide 18ug)
Study NCT03990454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor
Study NCT00005639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: subcutaneous injection (SC)
Study NCT00005639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: continuous intravenous (CIV)
Study NCT03118648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scale Action Research Arm Test (ARAT)
Description: Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
Study NCT04068870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive management program
Description: The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
Study NCT02591290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular (2 doses with 8-week interval)
Study NCT02688478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phthalate
Description: Delivered by inhalation on day 1 of the triad
Study NCT02688478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air
Description: Delivered by inhalation on day 1 of the triad
Study NCT02688478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subject specific allergen is delivered by inhalation on day 1 of the triad
Study NCT02688478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is delivered by inhalation on day 1 of the triad
Study NCT01433692 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Intervention
Description: CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
Study NCT01832974 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion
Study NCT01433692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
Study NCT00541736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
Study NCT00541736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Description: Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
Study NCT04248686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CoED Online Intervention
Description: Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
Study NCT03825445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa (Fertipeptil 0.1mg)
Description: Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
Study NCT03825445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Pregnyl 5000IU)
Description: hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
Study NCT02171949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of bone marrow mononuclear cells.
Description: Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
Study NCT04016987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated structured education intervention based on an app and artificial intelligence
Description: In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
Study NCT01809197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
Study NCT01809197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
Study NCT01809197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)
Description: Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
Study NCT01809197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Multi-Purpose Solution (MPS)
Description: Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
Study NCT01832974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion
Study NCT02433730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: intramuscular injection
Study NCT02433730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: intramuscular injection
Study NCT02680080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: a single 400 mg tablet of Moxifloxacin
Study NCT02680080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit group
Description: one liter of fresh pink-grapefruit juice
Study NCT02730429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib/placebo
Description: Palbociclib or a placebo is administered together with standard of care letrozole
Study NCT02730429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is standard of care in both arms
Study NCT00901589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: marine n-3 polyunsaturated fatty acids
Description: Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
Study NCT02730429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole is standard of care in both arms
Study NCT03147261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
Study NCT01370356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Tartrate
Description: Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
Study NCT01370356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
Study NCT04284670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
Study NCT03197597 — intervention group
Intervention type: OTHER
Intervention: Strain isolation from the nasopharynx
Description: B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
Study NCT02446483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idiazole 20mg DR tabs
Description: Delayed release tablets containing 20 mg of rabeprazole
Study NCT02446483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
Study NCT03208244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinically prescribed direct acting antiviral
Description: HCV treatment for 12 weeks
Study NCT00901589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: thistle oil
Description: four capsules a day
Study NCT00901589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: marine n-3 polyunsaturated fatty acids
Description: Four capsules daily, 2.2 g marine n-3 PUFAs in total
Study NCT00901589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thistle oil
Description: Four capsules daily
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Description: 8mg or 16mg
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Azelnidipine
Description: 8mg or 16mg
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: 4mg or 8mg
Study NCT02398175 — intervention group
Intervention type: OTHER
Intervention: reanimation/intubation
Study NCT04999176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
Study NCT04999176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
Study NCT02941991 — intervention group
Intervention type: BIOLOGICAL
Intervention: hESC-RPE
Description: sub-retinal injection
Study NCT00654680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
Study NCT00654680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Perindopril
Description: 4mg or 8mg
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: 12.5mg or 25mg
Study NCT01819441 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: hydrochlorothiazide
Description: 12.5mg or 25mg
Study NCT01510223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase.
Study NCT01510223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil and fish powder
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase.
Study NCT01510223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil and macadamia oil
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase.
Study NCT01510223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deadaptation
Description: A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.